In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted

Journal of Virology

Volumn 72, Issue 3, 1998, Pages 2022-2032

  Lusky, M ^a   Christ, M ^a   Rittner, K ^a   Dieterle, A ^a   Dreyer, D ^a   Mourot, B ^a   Schultz, H ^a   Stoeckel, F ^a   Pavirani, A ^a   Mehtali, M ^a  

^a TRANSGENE S A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; GENE DELETION; GENOME; IMMUNOCOMPETENCE; IMMUNOGENICITY; PRIORITY JOURNAL; TRANSGENE;

EID: 0031888263     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.3.2022-2032.1998     Document Type: Article

References (67)

1. Armentano, D., J. Zabner, C. Sacks, C. C. Sookdeo, M. P. Smith, J. A. St. George, S. C. Wadsworth, A. E. Smith, and R. J. Gregory. 1997. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71:2408-2416.
2. Barr, D., J. Tubb, D. Fergusson, A. Scaria, A. Lieber, C. Wilson, J. Perkins, and M. A. Kay. 1995. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2:151-155.
3. Berkner, K. L. 1988. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 6:616-629.
4. Bondesson, M., K. Ohman, M. Mannervik, S. Fan, and G. Aküsjarvi. 1996. Adenovirus E4 open reading frame 4 protein autoregulates E4 transcription by inhibiting E1A transactivation of the E4 promoter. J. Virol. 70:3844-3851.
5. Bosma, G. C., M. C. Custer, and M. J. Bosma. 1983. A severe combined immunodeficiency mutation in the mouse. Nature (London) 301:527-530.
6. Bridge, E., and G. Ketner. 1989. Redundant control of adenovirus late gene expression by early region 4. J. Virol. 63:631-638.
7. Bridge, E., S. Medghalchi, S. Ubol, M. Leesong, and G. Ketner. 1993. Adenovirus early region 4 and viral DNA synthesis. Virology 193:794-801.
8. Brough, D. E., V. Cleghon, and D. F. Klessig. 1992. Construction, characterization, and utilization of cell lines which inducibly express the adenovirus DNA-binding protein. Virology 190:624-634.
9. Brough, D. E., A. Lizonova, C. Hsu, V. A. Kulesa, and I. Kovesdi. 1996. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J. Virol. 70:6197-6501.
10. Challberg, S. S., and G. Ketner. 1981. Deletion mutants of adenovirus 2: isolation and initial characterization of virus carrying mutations near the right end of the viral genome. Virology 114:196-209.
11. Chartier, C., E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70:4805-4810.
12. Christ, M., M. Lusky, F. Stoeckel, D. Dreyer, A. Dieterle, A. I. Michou, A. Pavirani, and M. Mehtali. 1997. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol. Lett. 57:19-25.
13. Chroboczek, J., F. Bieber, and B. Jacrot. 1992. The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 186:280-285.
14. Connelly, S., J. M. Gardner, R. M. Lyons, A. McLelland, and M. Kaleko. 1996. Sustained expression of therapeutic levels of human factor VIII in mice. Blood 87:4671-4677.
15. Connelly, S., T. A. G. Smith, G. Dhir, J. M. Gardner, M. G. Mehaffey, K. S. Zaret, A. McLelland, and M. Kaleko. 1995. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum. Gene Ther. 6:185-193.
16. Dai, Y., E. M. Schwartz, D. Gu, W. W. Zhang, N. Sarvetnick, and I. M. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92:1401-1405.
17. Dedieu, J. F., E. Vigne, C. Torrent, C. Jullien, I. Mahfouz, J. M. Caillaud, N. Aubailly, C. Orisini, J. M. Guillaume, P. Opolon, P. Delaere, M. Perricaudet, and P. Yeh. 1997. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J. Virol. 71:4626-4637.
18. Dobner, T., N. Horikoshi, S. Rubenwolf, and T. Shenk. 1996. Blockage by adenovirus E4-ORF6 of transcriptional activation by the p53 tumor suppressor. Science 272:1470-1473.
19. Engelhardt, J. F., L. Litzky, and J. M. Wilson. 1994. Prolonged transgene expression in cotton rat lung with recombinant adenovirus defective in E2a. Hum. Gene Ther. 5:1217-1229.
20. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson. 1994. Ablation of E2a in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91:6196-6200.
21. Fang, B., H. Wang, G. Gordon, D. A. Bellinger, M. S. Read, K. M. Brinkhous, S. L. C. Woo, and R. C. Eisensmith. 1996. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E1A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther. 3:217-222.
22. Fasel, N., K. Pearson, E. Buetti, and H. Diggelmann. 1982. The region of mouse mammary tumor virus DNA containing the long terminal repeat includes a long coding sequence and signals for hormonally regulated transcription. EMBO J. 1:3-7.
23. Gao, G. P., Y. Yang, and J. M. Wilson. 1996. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70:8934-8943.
24. Goldman, M. J., L. A. Litzky, J. F. Engelhardt, and J. M. Wilson. 1995. Transfer of the CFTR gene to the lung of non-human primates with E1-deleted, E2A-defective recombinant adenovirus: a preclinical toxicology study. Hum. Gene Ther. 6:839-851.
25. Gossen, M. S. Freundlieb, G. Bender, G. Muller, W. Hille, and H. Bujard. 1995. Transcriptional activation by tetracyclines in mammalian cells. Science 268:1766-1769.
26. Gorziglia, M. I., M. J. Kadan, S. Yei, J. Lim, G. M. Lee, R. Luthra, and B. C. Trapnell. 1996. Elimination of both E1 and E2A from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70: 4173-4178.
27. Graham, F. L., and L. Prevec. 1991. Manipulation of adenovirus vectors, p. 109-128. In E. J. Murray (ed.), Methods in molecular biology, vol. 7. The Humana Press Inc., Clifton, N.J.
28. Graham, F. L., and L. Prevec. 1992. Adenovirus based expression vectors and recombmant vaccines, p. 363-390. In R. W. Ellis (ed.), Vaccines: new approaches to immunological problems. Butterworth-Heinemann, London, United Kingdom.
29. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-72.
30. Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467.
31. Henry, L., D. Xia, M. Wilke, J. Deisenhofer, and R. Gerard. 1994. Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J. Virol. 68:5239-5246.
32. Juillard, V., P. Villefroy, D. Godfrin, A. Pavirani, A. Venet, and J. G. Guillet. 1995. Long term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Immunol. 25:3467-3473.
33. Kass-Eisler, A., E. Falck-Pedersen, D. H. Elfenbein, M. Alvira, P. M. Buttrick, and L. A. Leinwand. 1994. The impact of development stage, route of administration, and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1:395-402.
34. Krougliak, V., and F. L. Graham. 1995. Development of cell lines capable of complementing E1, E4 and protein IX defective adenovirus type 5 mutants. Hum. Gene Ther. 6:1575-1586.
35. Lathe, R., J. L. Vilotte, and A. J. Clark. 1987. Plasmid and bacteriophage vectors for excision of intact inserts. Gene 57:193-201.
36. Leroy, P., A. I. Michou, and M. Lusky. Unpublished observations.
37. Li, Q., M. A. Kay, M. Finegold, L. D. Stratford-Perricaudet, and S. L. Woo. 1993. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4:403-409.
38. Lusky, M., and M. Christ. Unpublished observations.
39. Lusky, M., and B. Mourot. Unpublished observations.
40. Michou, A. I., L. Santoro, M. Christ, V. Juillard, A. Pavirani, and M. Mehtali. 1997. Adenovirus-mediated gene therapy: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther. 4:473-482.
41. Miller, S. A., D. D. Dykes, and H. F. Polesky. 1988. A simple salting out procedure for extracting DNA from nucleated cells. Nucleic Acids Res. 16:1215.
42. Moore, M. N., S. Horikoshi, and T. Shenk. 1996. Oncogenic potential of the adenovirus E4-ORF6 protein. Proc. Natl. Acad. Sci. USA 93:11295-11301.
43. Morral, N., W. O'Neal, H. Zhou, C. Langston, and A. Beaudet. 1997. Immune response to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2A wild-type and E2A-deleted vectors. Hum. Gene Ther. 8:1275-1286.
44. Reich, N. C. P., P. Sarnow, E. Duprey, and A. J. Levine. 1983. Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology 128:480-484.
45. Rittner, K., H. Schultz, A. Pavirani, and M. Mehtali. 1997. Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro. J. Virol. 71:3307-3311.
46. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
47. Shenk, T. 1996. Adenoviridae: the viruses and their replication, p. 2111-2148. In B. N. Fields, D. M. Knipe, P. M. Howley, et al. (ed.), Virology. Raven Press, Philadelphia, Pa.
48. Smith, C. A., L. S. Woodruff, G. R. Kitchingman, and C. M. Rooney. 1996. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J. Virol. 70:6733-6740.
49. Smith, T. A. G., M. G. Mehaffey, D. B. Kayda, J. M. Saunders, S. Yei, B. C. Trapnell, A. McLelland, and M. Kaleko. 1993. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet. 5:392-402.
50. Song, W., H.-L. Kong, P. Traktman, and R. G. Crystal. 1997. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum. Gene Ther. 8:1207-1217.
51. Stratford-Perricaudet, L. D., I. Makeh, M. Perricaudet, and P. Briand. 1992. Widespread long-term gene transfer to mouse skeletal muscles and heart. J. Clin. Invest. 90:626-630.
52. Trapnell, B. C. 1993. Adenoviral vectors for gene transfer. Adv. Drug Deliv. Rev. 12:185-199.
53. Tripathy, S. K., H. B. Black, E. Goldwasser, and J. M. Leiden. 1996. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2:545-550.
54. Wadsworth, S. C., H. Zhou, A. E. Smith, and J. M. Kaplan. 1997. Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T lymphocyte killing in vivo. J. Virol. 71:5189-5196.
55. Wang, Q., C. Greenburg, D. Bunch, D. Farson, and M. H. Finer. 1997. Persistent transgene expression in mouse liver following in vivo gene transfer with ΔE1/ΔE4 adenovirus vectors. Gene Ther. 4:393-400.
56. Wang, Q., X. C. Jia, and M. H. Finer. 1995. A packaging cell line for the propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. 2:775-783.
57. Weinberg, D. H., and G. Ketner. 1983. A cell line that supports the growth of a defective early region 4 mutant of human adenovirus type 2. Proc. Natl. Acad. Sci. USA 80:5383-5386.
58. Worgall, S., G. Wolff, E. Falck-Pederson, and R. G. Crystal. 1997. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8:37-44.
59. Yang, Y., H. C. J. Ertl, and J. M. Wilson. 1994. MHC class I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1:433-442.
60. Yang, Y., K. U. Jooss, Q. Su, H. C. Ertl, and J. M. Wilson. 1996. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3:137-144.
61. Yang, Y., F. A. Nunes, K. Berencsi, E. Furth, E. Gönczöl, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
62. Yang, Y., F. A. Nunes, K. Berencsi, E. Gönczöl, J. F. Engelhardt, and J. M. Wilson. 1994. Inactivation of E2A in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7:362-369.
63. Yang, Y., Q. Su, I. S. Grewal, R. Schiltz, R. A. Flavell, and J. M. Wilson. 1996. Transient subversion of CD40 ligand function diminishes immune response to adenovirus vectors in mouse liver and lung tissues. J. Virol. 70:6370-6377.
64. Yang, Y., I. Qin, H. J. C. Ertl, and J. M. Wilson. 1995. Cellular and humoral immune response to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004-2015.
65. Yeh, P., J. F. Dedieu, C. Orsini, E. Vigne, P. Denefle, and M. Perricaudet. 1996. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol. 70:559-565.
66. Zhou, H., W. O'Neal, N. Morral, and A. L. Beaudet. 1996. Development of a complementation cell line and a system for construction of adenovirus with E1 and E2A deleted. J. Virol. 70:7030-7038.
67. Zsengeller, Z. K., S. E. Wert, W. M. Hull, X. Hu, S. Yei, B. C. Trapnell, and J. A. Whitsett. 1995. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum. Gene Ther. 6:457-467.